Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles

New York Times Examines Program To Help Orphans Survive 'Fragile Days Of Infancy'
The New York Times examines a program being offered at an orphanage in Tanzania that provides emotional and physical support for newborns and young children who are at a high risk of death after losing their mothers in infancy. "Africa is full of at least 50 million orphans, the legacy of AIDS and other diseases, war and high rates of death in pregnancy and childbirth," the newspaper writes. "With the numbers increasing every day, Africans are struggling to care for them, often in ways that differ strikingly from the traditional concept of an orphanage in the developed world."

Novartis Successfully Demonstrates Capabilities Of Cell-based Technology For Production Of A(H1N1) Vaccine
Novartis has successfully completed the production of the first batch of influenza A(H1N1) vaccine, weeks ahead of expectations. Cell-based manufacturing technology[1] allows vaccine production to be initiated once a pandemic virus strain is identified without the need to adapt the virus strain to grow in eggs, as with traditional vaccine technologies. This advance has cut weeks off the time required to begin vaccine production. This first batch of ten liters of wild type influenza A(H1N1) vaccine monobulk will be used for pre-clinical evaluation and testing and is also being considered for use in clinical trials. It demonstrates the value of the cell-based production approach, that is also being used by Novartis with reassortant influenza A(H1N1) seed.
News of the day
Link Between Extreme Glucose Levels In Diabetic Patients With Heart Failure And Increased Risk Of Death
Compared with patients with moderately controlled glucose levels, diabetic patients who have heart failure and either too high or too low glucose levels may be at increased risk of death, said researchers at Baylor College of Medicine in a report published in the current issue of Journal of the American College of Cardiology.
Health Insurance

IPS Examines Need For New Drugs To Treat Neglected Tropical Diseases

Inter Press Service News Agency examines the shortcomings of treatments for neglected tropical diseases - which, according to the Drugs for Neglected Diseases Initiative (DNDi), account "for 12 percent of the global disease burden," and 1.3 percent of the new drugs developed between 1975 to 2004. "The diseases in question account for the deaths of 500,000 people annually, mostly in sub-Saharan Africa, but drug development is biased towards the prospect of high profits, which diseases of the poor like sleeping sickness and visceral leishmaniaisis are unable to offer," IPS writes. "The pharmaceutical industry does not see neglected diseases as a market, because these diseases affect poor people with few res. Therefore they are not a big market," Marcel Tanner, chairman of the DNDi board of directors, told IPS during a meeting last month in Nairobi to discuss new ways to tackle NTDs. "Existing therapies [for neglected tropical diseases] are often toxic, prohibitively costly and difficult to administer," and overwhelm health personnel, IPS writes. The article also addresses efforts to prevent the spread of neglected tropical diseases, through the distribution of insecticide-treated nets and improved sanitation (Mulama, 7/6). This information was reprinted from globalhealth.kff.org with kind permission from the Henry J. Kaiser Family Foundation. You can view the entire Kaiser Daily Global Health Policy Report, search the archives and sign up for email delivery at globalhealth.kff.org. © Henry J. Kaiser Family Foundation. All rights reserved.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009